γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO - Wikidata - awgldk - TriplyDB

γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO

γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO

http://www.wikidata.org/entity/Q34630290

about

Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials Trimethylamine N-Oxide: The Good, the Bad and the Unknown Intestinal Microbiota Metabolism and Atherosclerosis Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis Serum Trimethylamine N-oxide, Carnitine, Choline, and Betaine in Relation to Colorectal Cancer Risk in the Alpha Tocopherol, Beta Carotene Cancer Prevention Study.The gut microbiome in cardio-metabolic health.HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort.Microbial-Host Co-metabolites Are Prodromal Markers Predicting Phenotypic Heterogeneity in Behavior, Obesity, and Impaired Glucose Tolerance Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease Determination of trimethylamine-N-oxide in combination with L-carnitine and γ-butyrobetaine in human plasma by UPLC/MS/MS.Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota.Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk Intestinal Immunity and Gut Microbiota in Atherogenesis.Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk.Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association.Gut Microbiota in Cardiovascular Health and Disease.Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery.Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB.Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans.Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden Zonulin Regulates Intestinal Permeability and Facilitates Enteric Bacteria Permeation in Coronary Artery Disease.Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk.Untargeted metabolomics of colonic digests reveals kynurenine pathway metabolites, dityrosine and 3-dehydroxycarnitine as red versus white meat discriminating metabolites.Metabolic profiling in human exposome studies.Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.Obstructive Sleep Apnea-Induced Hypertension: Role of the Gut Microbiota.Genomics and metagenomics of trimethylamine-utilizing Archaea in the human gut microbiome.Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.Uncovering the trimethylamine-producing bacteria of the human gut microbiota.Microbiome therapeutics - Advances and challenges.Microbiome, trimethylamine N-oxide, and cardiometabolic disease.Alterations in the gut microbiota can elicit hypertension in rats.

P2860

Q26751203-512CF123-9F89-490E-84A3-5688B9A7BA30 Q26823198-FB373E78-84DD-4199-A8B5-742969233FB9 Q26865600-35260D37-71ED-4BCA-AF58-2BB5A10324B1 Q28077742-C3FB7768-BB97-44CD-910A-8EE121A619CD Q28079182-3A6E5778-F2B7-411A-BE23-9F148D1614C6 Q28081862-37BD9AE8-FAE2-4D06-8511-484D7D77A1CA Q29038812-2293D253-DF61-4A1E-B986-CBF380493521 Q30275023-D0AD6408-C9C8-4D5C-A5AA-7740EDA5095E Q30373247-EAAA94A5-F46A-43C3-82EF-0D9A35E38872 Q30839904-4F14A3DB-7E96-44F0-81EC-3D5964FBBD80 Q33560362-4919B921-D25D-4536-A15F-0222BAA1EB76 Q33899037-CD10D8D3-13D5-4551-9C43-29FBB3786EA8 Q35033613-21DEFA64-F6AC-42B3-B8F0-CEA7F13E1429 Q35601213-DB19C1B8-821E-4531-B364-C69DB0B6D216 Q35662826-522CEA20-671C-4692-AA07-94F14E83BB7A Q35955435-F1F6FB1B-E795-4773-A063-17404E27B886 Q36215494-560CF3B5-971A-46B6-8BD9-BD03223C61BA Q36228851-34CD6971-B32E-462C-9D43-B9AB03DC98A5 Q36328994-D8B589BA-3793-4ACD-BAD3-2D2AEA38DE6C Q36329055-A3334F69-FFBF-475D-806F-B6389157B110 Q36337990-F0590469-EBEB-447C-9299-588C11FB498F Q36340545-FC01EC90-63B5-44B1-8816-CBBEF13DA862 Q36714031-65D01C33-138A-4950-A868-414F4FE1BEC7 Q36827878-016E5B2D-4585-4304-88A4-7E816CAC7CA4 Q36941666-B6959259-7D73-41E8-B617-DDBB29CFC671 Q36968992-CED559FE-56E5-4D3F-B4EC-54DBF572C6DA Q37050072-4989FDBD-57B0-42DA-9B94-7597B33CB0E6 Q37090184-CC3BE4D9-BA2D-46F4-B693-07EC99EA0D55 Q37357727-38813B45-04BD-406F-9863-CDDCE47D1B5B Q37595816-DFB4FF12-4938-4195-9E0E-A221B964B09B Q37640243-FEE6F8B3-05D7-4E6C-8CA8-4D24152C455A Q38570003-9309C46B-A08A-40A6-8B1B-C79DCD8878C2 Q38701617-44760217-DECC-4BAD-A417-47BB08AE1025 Q38736599-07D349A3-04B5-482E-B360-37923E9706FE Q38741089-5B035D67-9F48-45A9-A08B-B421B31A678F Q38769993-D8A6689C-D571-4A70-A5B9-A63C767F4098 Q38785297-7ECD194C-81F0-4A97-A7A1-00C326DCCEAF Q38829360-162DBBA4-2894-4BFF-9827-3F151A37BB35 Q38918147-071FCAAE-7CB9-4DB2-9DFC-F5FD6DBAC724 Q39067441-3B2F8641-68D0-49CB-ABDC-7B4BEC755960

P2860

γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO

http://www.wikidata.org/entity/Q34630290

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@ast

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@en

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@nl

type

label

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@ast

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@en

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@nl

prefLabel

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@ast

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@en

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@nl

P1433

Q34630290-A61830D9-62AB-492A-935B-AD4BE03D6B43

P1476

Q34630290-3CEDD7B6-DAAD-4D04-997B-1B5247962F30

P2093

Q34630290-282366CC-3177-4283-B6A7-BB546D9881B7

Q34630290-3B8EDCCD-7864-4FE3-8AA8-2881EED1867B

Q34630290-3E9BB522-FA9A-4AFA-8671-3C5ABEEA0A67

Q34630290-4AC86382-E380-4C43-BDCC-68FCDFC89E6A

Q34630290-575BFAB2-A28B-491B-9AA4-E92341ACE86D

Q34630290-867FC4FD-3B13-4CD3-9208-073750DA01CF

Q34630290-BCF5D81F-3F40-46C8-A850-43603E014D33

Q34630290-BD6E9828-D974-427B-A6EE-47B7FBF6DE51

Q34630290-E9283FBC-4CB7-4234-AC38-CDD87E41D5CD

P2860

Q34630290-02C92401-9395-4B7F-969A-0790165EF5F0

Q34630290-044AA6CC-646C-4878-B584-AA82F02E7DA8

Q34630290-0F0EE2FD-E94E-4A32-AC82-52F959CFBE46

Q34630290-11E69844-583B-43E7-8E77-FD19AA4BC37E

Q34630290-14A6BD5C-703D-4289-A8C0-21C7D0FC0D58

Q34630290-1C7C2504-B795-4CC1-9835-6833B7A94C27

Q34630290-1E8A42CD-5435-4C9E-A065-67F3545D450F

Q34630290-23B840CF-A598-4812-B96E-CD1CBAD5B104

Q34630290-24A5370E-10E5-4DEA-A4B5-3049E2B421A5

Q34630290-323924B5-3E24-49BD-B449-AD769D436877

P304

Q34630290-32BEA69A-9B28-4471-9B36-5383661D8D3C

P31

Q34630290-C28114CE-7CD8-49DE-9560-8B1E8F3E7514

P356

Q34630290-E5D8A97C-F589-40FA-A651-7DE6CEA75086

P433

Q34630290-8FFDA6DE-2CB9-4EB9-9A90-6D9B55E4E4DD

P478

Q34630290-6CB580E2-6EF8-4969-AE65-5D32B9498EED

P50

Q34630290-1533E8B9-488A-4B25-80FB-214C8BC961EA

Q34630290-5972A3E2-EB97-4761-BC58-A678FF06B30A

Q34630290-D77C8B97-27E4-44CF-821D-A1C91E148C97

Q34630290-DF9A9FBD-33C2-43A9-B19E-7EE6D8E7B30A

Q34630290-F2B48D8F-34AF-436A-8DEC-84744AD2E018

P577

Q34630290-8A79EDF8-12C2-452B-B2AD-31564C7D6F51

P5875

Q34630290-6C9C0D62-F588-4B6F-B466-C16E32D6B374

P698

Q34630290-F6E5F610-D304-4537-B063-3EB7A7353627

P921

Q34630290-5108D087-915D-4557-B1E2-3F6B11B1A032

P932

Q34630290-1E6C486A-8079-42AC-9FE7-632B30DAFBAF

P356

J.CMET.2014.10.006

P1433

Cell Metabolism

P1476

γ-Butyrobetaine is a proathero ...... abolism of L-carnitine to TMAO

@en

P2093

Jennifer A Buffa

http://www.w3.org/2001/XMLSchema#string

Jill C Gregory

http://www.w3.org/2001/XMLSchema#string

Joseph A DiDonato

http://www.w3.org/2001/XMLSchema#string

Lin Li

http://www.w3.org/2001/XMLSchema#string

Miranda K Culley

http://www.w3.org/2001/XMLSchema#string

Robert A Koeth

http://www.w3.org/2001/XMLSchema#string

Stanley L Hazen

http://www.w3.org/2001/XMLSchema#string

W H Wilson Tang

http://www.w3.org/2001/XMLSchema#string

Yuping Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Obesity alters gut microbial ecology

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk

Linking long-term dietary patterns with gut microbial enterotypes

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

Antibiotics in early life alter the murine colonic microbiome and adiposity

The contributory role of gut microbiota in cardiovascular disease

The gut microbiota as an environmental factor that regulates fat storage

Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation

Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites

P304

799-812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CMET.2014.10.006

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Bruce S. Levison

Aldons Jake Lusis

Jonathan D Smith

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268687690

http://www.w3.org/2001/XMLSchema#string

P698

25440057

http://www.w3.org/2001/XMLSchema#string

P921

(3R)-3-hydroxy-4-oxobutanoate

P932

4255476

http://www.w3.org/2001/XMLSchema#string